Liraglutide

1. Liraglutide is a human glucagon like peptide-1 (GLP-1) analogue used in the treatment of diabetes.

Drug name: Liraglutide

Nickname: Victoza

Foreign name:Liraglutide injection

Main indications: adult type 2 diabetes

Usage and dosage:

The recommended daily dose is no more than 1.8mg

Adverse reactions:

Injection site reaction

Active ingredient:Liraglutide(human glucagon like peptide-1 (GLP-1) analogue produced by yeast through gene recombination technology)

Chemical name: arg34lys26 - (n - ε - (γ - Glu (n - α - hexadecyl))) - GLP-1 [7-37]

Chemical structure formula:

Molecular formula: c172h265n43o51

Molecular weight: 3751.20 Da

Other ingredients: disodium hydrogen phosphate dihydrate, propylene glycol, hydrochloric acid and / or sodium hydroxide (only as pH regulator), phenol and water for injection

Liraglutideproperties:

This product is a colorless or almost colorless clear isotonic solution; pH = 8.15

Indication:

This product is used to control blood glucose in adult patients with type 2 diabetes

It is suitable for patients with poor blood glucose control after treatment with metformin or sulfonylurea alone at the maximum tolerable dose. It is used in combination with metformin or sulfonylurea.

Specifications

3 ml: 18 mg (pre filled pen).

Usage and dosage

2, usage

This product is injected once a day, and can be injected at any time without taking medicine according to the meal time. This product is injected subcutaneously. The injection site can be abdomen, thigh or upper arm. Dose adjustment is not necessary to change the injection site and time. However, it is recommended that this product be injected at the same time every day, and the most convenient time should be chosen. For more instructions on administration, refer to the precautions for use and other operations.

This product should not be injected intravenously or intramuscularly.

3, dosage

The initial dose of Liraglutide was 0.6mg/day. After at least one week, the dose should be increased to 1.2mg. Some patients are expected to benefit from increasing the dose from i.2mg to 1.8mg. According to the clinical response, in order to further improve the hypoglycemic effect, at least one week later

Increase the dose to 1.8mg. The recommended daily dose is no more than 1.8mg.

This product can be used in combination with metformin without changing the dose of metformin.

This product can be used in combination with sulfonylureas. When this product is used in combination with sulfonylureas, consideration should be given to reducing the dosage of sulfonylureas to reduce the risk of hypoglycemia (see Precautions).

When adjusting the dosage of this product, self blood glucose monitoring is not necessary. However, when this product is combined with sulfonylureas to adjust the dosage of sulfonylureas, self blood glucose monitoring may be necessary.

4. Adverse reactions

Injection site reaction

In long-term (26 weeks or longer) control trials, about 2% of subjects receiving this product reported injection site reactions. These reactions are usually mild and will not lead to discontinuation of the product. [1]

taboo

Allergic to the active ingredients or any other auxiliary materials in this product.

Matters needing attention

This product should not be used in patients with type 1 diabetes or in the treatment of diabetic ketoacidosis.

This product should not be used in patients with a past or family history of medullary thyroid cancer (MTC) and patients with type 2 multiple endocrine tumor syndrome (MEN 2).

This product has limited experience in the treatment of congestive heart failure patients with NYHA grade I-II. There is no application experience in patients with congestive heart failure with NYHA grade III-IV.

Because of the limited experience in the treatment of inflammatory bowel disease and diabetic gastroparesis, this product is not recommended for these patients.

The treatment of this product will be accompanied by a transient gastrointestinal adverse reactions, including nausea, vomiting and diarrhea.

The use of other GLP-1 analogues has been found to be associated with the risk of pancreatitis.

There are a few reports of acute pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis: persistent and severe abdominal pain. If pancreatitis is suspected, discontinue this product and other potentially suspicious drugs.

Some clinical trials have reported thyroid adverse events, including elevated serum calcitonin, goiter and thyroid tumor, especially in patients with previous thyroid disease (see adverse reactions). Patients treated with this product in combination with sulfonylurea may have an increased risk of hypoglycemia (see adverse reactions). Reducing the dosage of sulfonylureas can reduce the risk of hypoglycemia.

Impact on driving and mechanical operation

The effect of this product on driving and mechanical operation has not been studied. Patients should be informed to prevent hypoglycemia when driving and operating machinery, especially when the product is combined with sulfonylureas.

Special precautions for use and other operations

This product can only be used when it is colorless and clear.

This product should not be used after freezing.

This product should be used with Noho needle as long as 8mm and as thin as 32g.

This product does not contain injection needles.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.